睡眠体位疗法 compared with 气道正压疗法对轻中度体位依赖性阻塞性睡眠呼吸暂停患者日间嗜睡的非劣效性:多中心随机交叉试验研究方案
本研究为多中心、非劣效、开放标签随机交叉试验,计划纳入418例轻中度体位依赖性阻塞性睡眠呼吸暂停(POSA)且日间嗜睡(ESS>10分)患者,1:1随机先后接受气道正压(PAP)疗法或睡眠体位疗法(SPT)各12周,洗脱期2周,主要结局为各治疗阶段末的ESS评分,以1.35为非劣效界值检验SPT的非劣效性。
要点
- 轻中度OSA(AHI 5-30/h)患者中至少一半为体位依赖性OSA(POSA),呼吸暂停主要发生于仰卧位睡眠。
- 研究比较SPT与PAP对日间嗜睡(ESS)的非劣效性,非劣效界值为1.35,单侧检验显著性水平2.5%。
- 计划纳入418例患者以达到80%把握度,假设脱落率5%,每序列220例。
核心结论
- 目前尚不清楚SPT在缓解轻中度POSA患者症状方面是否非劣效于PAP疗法,本研究旨在回答该问题。
研究设计与样本
- 多中心、非劣效、开放标签随机交叉临床试验,患者按1:1分配,按中心和AHI分层,先后接受PAP或SPT各12周,洗脱期2周。
- 计划纳入418例轻中度POSA且ESS>10分的患者,假设标准差为4、脱落率5%,每序列220例,并在300例时进行中期分析以评估可能的无效停止。
主要发现
- 主要结局为每个治疗阶段末由ESS测量的日间嗜睡,采用意向性治疗人群线性混合效应模型分析。
- 非劣效性检验采用单侧检验,显著性水平2.5%,非劣效界值为1.35。
关键数值与推荐
- 轻中度OSA定义为AHI 5-30/h,POSA指呼吸暂停主要发生于仰卧位睡眠。
- 日间嗜睡定义为ESS>10分。
- 非劣效界值为1.35,单侧检验显著性水平为2.5%。
临床怎么用
- PAP和SPT两种干预均作为试验指南的一部分由法定健康保险公司覆盖。
- 计划中心招募轻中度POSA患者可行。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: First-line therapy for patients with clinically relevant obstructive sleep apnoea (OSA) is positive airway pressure therapy (PAP). At least one half of patients with mild to moderate OSA (apnoea-hypopnoea-index (AHI) 5-30/h) have positional OSA (POSA), where apnoea occurs mostly in supine sleep. These patients might benefit from sleep-position therapy (SPT) which should reduce sleeping time spent in a supine position. Until now, it is unclear whether SPT is non-inferior to PAP therapy for symptom relief in these patients. METHODS: This is a multicentre, non-inferiority, open-label randomised, cross-over clinical trial. Patients with mild to moderate POSA and daytime sleepiness (according to Epworth Sleepiness Scale (ESS) > 10 points) will be randomised with a 1:1 allocation ratio, stratified by centre and AHI, to start with either PAP therapy or SPT and treated for 12 weeks. After a wash-out period of two weeks, they will switch to the other therapy for 12 weeks. The primary outcome is daytime sleepiness measured by the ESS at the end of each treatment phase. Analysis will be done in the intention-to-treat population using a linear mixed-effects model containing the intervention, the phase, the interaction between therapy and phase (including the carry-over effect) and the baseline measurement of the ESS and AHI as fixed effect, and centre and patient as random effects. A one-sided test at significant level of 2.5% will be used to test the non-inferiority of SPT with a non-inferiority margin of 1.35. Based on a sample size calculation with a one-sided one-sample t-test at significant level of 2.5%, assuming a standard deviation of 4, a total of 418 patients should be included to reach 80% power when SPT is only slightly inferior to PAP therapy (difference 0.8 resulting in a delta of 0.55 (1.35-0.8)). Assuming a 5% drop-out rate, 220 patients per sequence should be included. Possible futility stopping is planned at an interim analysis after 300 patients. DISCUSSION: The recruitment of patients with mild to moderate POSA is feasible with the planned centres. Both certified interventions (PAP and SPT) are covered by the statutory health insurance companies as part of the trial guideline. TRIAL REGISTRATION: DRKS00033048 registered 17. June 2024, http://www.drks.de .
引用
- Timmesfeld N, Neumann A, Valbert F, et al. Non-inferiority of sleep position therapy compared to positive airway pressure therapy with regard to daytime sleepiness in patients with mild to moderate position-dependent obstructive sleep apnoea (POSA): study protocol for a multicentre randomised cross-over trial. Trials. 2025. PMID: 40826110. doi:10.1186/s13063-025-09007-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。